MA H1337

Requires all Massachusetts health insurers, including the Group Insurance Commission, MassHealth, and private carriers, to cover opioid antagonists (like naloxone) and opioid agonists (like buprenorphine) for opioid use disorder treatment without prior authorization

Eliminates all cost-sharing requirements including deductibles, copayments, coinsurance, and out-of-pocket limits for these medications, unless the plan would lose tax-exempt status under the Internal Revenue Code

Removes the requirement for a prescription from a health care practitioner to obtain insurance coverage for opioid antagonists and agonists

Mandates coverage as a medical benefit when medications are dispensed at health care facilities and as a pharmacy benefit when dispensed by pharmacists, with medical benefit reimbursement capped at the average in-network pharmacy rate

Prohibits health care facilities from balance billing patients for these medications and requires insurers to reimburse facilities for costs when medications are directly dispensed or administered